Therapeutic antibodies have transformed targeted therapy by specifically binding to tumor biomarkers, enabling precise and effective treatment.

Their development involves multiple stages—from target identification and antibody generation to clinical trials, regulatory approval, and commercial production.

At Allianz Bio, in collaboration with our principals, we offer end-to-end solutions to support every stage of therapeutic antibody development, helping accelerate innovation from discovery to clinical application.